Info
Ownership

Charles Elliott Sigal - Insider Trading & Ownership

Location: 32 Brearly Road, Princeton, NJ
Summary: The estimated net worth of Charles Elliott Sigal is at least $928K dollars as of June 2, 2025. Charles Elliott Sigal is the Director of ALNYLAM PHARMACEUTICALS, INC. and owns shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) stock worth about $646K. Charles Elliott Sigal is the Director of Vir Biotechnology, Inc. and owns shares of Vir Biotechnology, Inc. (VIR) stock worth about $282K.
Signature: /s/ Vanina de Verneuil, Attorney-In-Fact
All Insider Reports: All Insider Reports

Ownership of Charles Elliott Sigal

Symbol	Company	Relationship	Holdings Value	Report Period
ALNY	ALNYLAM PHARMACEUTICALS, INC.	Director	$646K	May 8, 2025
VIR	Vir Biotechnology, Inc.	Director	$282K	May 30, 2025
ADAP	Adaptimmune Therapeutics PLC	Director		Jul 3, 2023
SURF	Surface Oncology, Inc.	Director		Sep 8, 2023

Showing 1 to 4 of 4 entries

Insider Transactions Reported by Charles Elliott Sigal:

Sym	Company	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership
VIR	Vir Biotechnology, Inc.	Common Stock	Award	+33.6%	$0	0.00	+8K	31.8K	5/30/2025	Direct
VIR	Vir Biotechnology, Inc.	Stock Option (Right to Buy)	Award		$0	0.00	+16K	16K	5/30/2025	Direct
ALNY	Alnylam Pharmaceuticals, Inc.	Common Stock	Award		$0	0.00	+775	775	5/8/2025	Direct
ALNY	Alnylam Pharmaceuticals, Inc.	Stock Option (right to buy)	Award		$0	0.00	+1.56K	1.56K	5/8/2025	Direct
VIR	Vir Biotechnology, Inc.	Common Stock	Award	+50.6%	$0	0.00	+8K	23.8K	5/30/2024	Direct
VIR	Vir Biotechnology, Inc.	Stock Option (Right to Buy)	Award		$0	0.00	+16K	16K	5/30/2024	Direct
ALNY	Alnylam Pharmaceuticals, Inc.	Stock Option (right to buy)	Award		$0	0.00	+5.23K	5.23K	5/16/2024	Direct
SURF	Surface Oncology, Inc.	Common Stock	Disposed to Issuer	-100%	$0		-45.5K	0	9/8/2023	See Footnote
SURF	Surface Oncology, Inc.	Stock Option (Right to Buy)	Disposed to Issuer	-100%	$0	0.00^*	-114K	0	9/8/2023	Direct
ADAP	Adaptimmune Therapeutics PLC	Option to purchase Ordinary Shares	Award		$0	0.00	+933K	933K	7/3/2023	Direct
VIR	Vir Biotechnology, Inc.	Common Stock	Award	+61.6%	$0	0.00	+6.03K	15.8K	5/22/2023	Direct
VIR	Vir Biotechnology, Inc.	Stock Option (Right to Buy)	Award		$0	0.00	+12.1K	12.1K	5/22/2023	Direct
ALNY	Alnylam Pharmaceuticals, Inc.	Stock Option (right to buy)	Award		$0	0.00	+3.45K	3.45K	5/18/2023	Direct
VIR	Vir Biotechnology, Inc.	Common Stock	Purchase	+33.3%	$56.8K	22.73	+2.5K	10K	3/1/2023	By Sigal Family Investments, LLC
VIR	Vir Biotechnology, Inc.	Common Stock	Purchase	+50%	$62.4K	24.96	+2.5K	7.5K	1/5/2023	By Sigal Family Investments, LLC
VIR	Vir Biotechnology, Inc.	Common Stock	Purchase	+100%	$63.1K	25.25	+2.5K	5K	1/4/2023	By Sigal Family Investments, LLC
VIR	Vir Biotechnology, Inc.	Common Stock	Purchase		$64K	25.60	+2.5K	2.5K	1/3/2023	By Sigal Family Investments, LLC
ALNY	Alnylam Pharmaceuticals, Inc.	Stock Option (right to buy)	Award		$0	0.00	+4.46K	4.46K	8/22/2022	Direct
ADAP	Adaptimmune Therapeutics PLC	Option to purchase Ordinary Shares	Award		$0	0.00	+737K	737K	7/1/2022	Direct
SURF	Surface Oncology, Inc.	Stock Option (Right to Buy)	Award		$0	0.00	+24K	24K	6/8/2022	Direct
VIR	Vir Biotechnology, Inc.	Common Stock	Award	+189.8%	$0	0.00	+6.41K	9.78K	5/23/2022	Direct
VIR	Vir Biotechnology, Inc.	Stock Option (Right to Buy)	Award		$0	0.00	+12.8K	12.8K	5/23/2022	Direct
ADAP	Adaptimmune Therapeutics PLC	Option to purchase Ordinary Shares	Award		$0	0.00	+474K	474K	7/1/2021	Direct
SURF	Surface Oncology, Inc.	Stock Option (Right to Buy)	Award		$0	0.00	+17.7K	17.7K	6/8/2021	Direct
VIR	Vir Biotechnology, Inc.	Common Stock	Award		$0	0.00	+3.37K	3.37K	5/21/2021	Direct
VIR	Vir Biotechnology, Inc.	Stock Option (Right to Buy)	Award		$0	0.00	+6.75K	6.75K	5/21/2021	Direct

Previous1Next

Showing 1 to 26 of 26 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.